Denmark’s updated digital clinical trial guidance introduces three critical changes that directly impact how multinational research will operate across Europe. First, complete alignment with the EU common framework ensures regulatory consistency, reducing compliance complexity for trial sponsors operating in multiple jurisdictions. Second, newly established cross-border participation provisions eliminate geographic barriers, allowing patients throughout the EU to access trials previously limited to their home countries.
Third, enhanced digital technology integration requirements formalise standards for remote patient monitoring and virtual consultations, ensuring data quality and participant safety across borders. For researchers, this means streamlined recruitment processes and larger trial pools. For patients, particularly those with rare conditions, it represents unprecedented access to cutting-edge research opportunities. These provisions reflect lessons learned during COVID-19, when digital solutions proved essential for maintaining research continuity.
Read the full article on GMJ Newsroom.
Was this article helpful?
